REGENXBIO Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
RGNX$8.07+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share data)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $57,526 | $34,522 |
| Marketable securities | 177,161 | 240,736 |
| Accounts receivable (net of allowance of $4,587 as of December 31, 2023) | 20,473 | 24,790 |
| Prepaid expenses | 9,067 | 14,520 |
| Other current assets | 13,774 | 20,403 |
| Total current assets | 278,001 | 334,971 |
| Marketable securities | 10,179 | 38,871 |
| Accounts receivable | 474 | 701 |
| Property and equipment, net | 117,589 | 132,103 |
| Operating lease right-of-use assets | 53,716 | 60,487 |
| Restricted cash | 2,030 | 2,030 |
| Other assets | 4,000 | 4,807 |
| Total assets | $465,989 | $573,970 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $22,798 | $22,786 |
| Accrued expenses and other current liabilities | 38,070 | 49,703 |
| Deferred revenue | 115 | 148 |
| Operating lease liabilities | 7,902 | 7,068 |
| Liability related to sale of future royalties | 34,309 | 50,567 |
| Total current liabilities | 103,194 | 130,272 |
| Operating lease liabilities | 74,131 | 82,222 |
| Liability related to sale of future royalties | 25,378 | 43,485 |
| Other liabilities | 3,635 | 6,249 |
| Total liabilities | 206,338 | 262,228 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock; $0.0001 par value; 100,000 shares authorized at December 31, 2024 and 2023; 49,549 and 44,046 shares issued and outstanding at December 31, 2024 and 2023, respectively | 5 | 4 |
| Additional paid-in capital | 1,192,536 | 1,021,214 |
| Accumulated other comprehensive loss | (741) | (4,429) |
| Accumulated deficit | (932,149) | (705,047) |
| Total stockholders’ equity | 259,651 | 311,742 |
| Total liabilities and stockholders’ equity | $465,989 | $573,970 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.